Dr. Katerina Gurova came to Roswell Park Cancer Institute (RPCI) from Cleveland BioLabs, where she served as Director of Anti-Cancer Drug Discovery. Before joining Cleveland BioLabs, she worked as a Project Scientist in the Department of Molecular Genetics at The Cleveland Clinic.Dr. Gurova earned her medical degree from the Sechenov Medical Academy and a doctoral degree in experimental oncology from the Blokhin Cancer Research Center, both located in Moscow, Russia.Dr. Gurova’s research interests are focused on the discovery and development of new anticancer drugs. Specifically, she identified a new class of prospective anticancer agents named curaxins which are capable of simultaneous targeting of several signal transduction pathways that are frequently deregulated in cancer, including p53 and NF-kappaB. Her laboratory at RPCI is working on deciphering molecular mechanisms, optimizing therapeutic properties of curaxins and on the development of new approaches to treatment of hormone-refractory prostate cancer.

discovery of new anti-cancer agents through different approaches, their testing and early stage development as well as understanding the mechanisms of their activity